Gain Therapeutics Inc (NASDAQ:GANX)’s traded shares stood at 0.56 million during the last session, with the company’s beta value hitting 0.23. At the close of trading, the stock’s price was $1.76, to imply an increase of 10.00% or $0.16 in intraday trading. The GANX share’s 52-week high remains $5.33, putting it -202.84% down since that peak but still an impressive 49.43% since price per share fell to its 52-week low of $0.89. The company has a valuation of $46.68M, with an average of 0.16 million shares in intraday trading volume over the past 10 days and average of 298.83K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Gain Therapeutics Inc (GANX), translating to a mean rating of 1.00. Of 13 analyst(s) looking at the stock, 0 analyst(s) give GANX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 12 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Gain Therapeutics Inc (NASDAQ:GANX) trade information
After registering a 10.00% upside in the last session, Gain Therapeutics Inc (GANX) has traded red over the past five days. The 5-day price performance for the stock is 12.10%, and 1.73% over 30 days. With these gigs, the year-to-date price performance is -46.09%. Short interest in Gain Therapeutics Inc (NASDAQ:GANX) saw shorts transact 0.66 million shares and set a 1.65 days time to cover.
The extremes give us $4 and $10 for target low and target high price respectively. As such, GANX has been trading -468.18% off suggested target high and -127.27% from its likely low.
Gain Therapeutics Inc (GANX) estimates and forecasts
Looking at statistics comparing Gain Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Gain Therapeutics Inc (GANX) shares are 37.50% up over the last 6 months, with its year-to-date growth rate higher than industry average at 41.52% against 16.40%.
GANX Dividends
Gain Therapeutics Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Gain Therapeutics Inc (NASDAQ:GANX)’s Major holders
Gain Therapeutics Inc insiders hold 5.09% of total outstanding shares, with institutional holders owning 7.96% of the shares at 8.39% float percentage. In total, 7.96% institutions holds shares in the company, led by TIMELO INVESTMENT MANAGEMENT INC.. As of 2024-06-30, the company held over 0.61 million shares (or 3.3666% of shares), all amounting to roughly $0.77 million.
The next major institution holding the largest number of shares is DME CAPITAL MANAGEMENT, LP with 0.57 million shares, or about 3.1488% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.72 million.
We also have Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Gain Therapeutics Inc (GANX) shares. Going by data provided on Oct 31, 2024 , Fidelity Extended Market Index Fund holds roughly 143.52 shares. This is just over 0.54% of the total shares, with a market valuation of $0.25 million. Data from the same date shows that the other fund manager holds a little less at 135.7, or 0.51% of the shares, all valued at about 0.24 million.
